PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.

CONCLUSION: PD-1 inhibition produces durable responses among patients with advanced or metastatic CSCC. PD-1 inhibition therapy is well tolerated, but patients should be monitored closely for immune-related adverse events, particularly frail or immune-suppressed patients. Further investigation of potential biomarkers to help identify patients who will derive the most benefit from this therapeutic option is needed.
PMID: 33210210 [PubMed - as supplied by publisher]

Source: Clin Med Res - November 18, 2020 Category: Research Authors: In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A Tags: J Cancer Res Clin Oncol Source Type: research